Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics today announced that it has received CE marking in Europe for its Tumor BRACAnalysis CDx test. 

The test identifies tumors with mutations in the BRCA1 and BRCA2 genes. Myriad said that Tumor BRACAnalysis CDx is the only CE-marked tumor-based companion diagnostic test. It identifies patients who may benefit from AstraZeneca's Lynparza (olaparib), a poly ADP-ribose polymerase inhibitor. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.